EKF Diagnostics Holdings PLC Notice of Results (9258Q)

TIDMEKF

RNS Number : 9258Q

EKF Diagnostics Holdings PLC

03 March 2021

This announcement contains inside information

for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR)

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

Notice of results

Investor presentation

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, will announce its preliminary results for the year ended 31 December 2020 on Tuesday 30 March 2021.

Investor briefing

EKF Diagnostics will be hosting a live online presentation open to all investors on Tuesday 30 March 2021 at 4.30pm, via video conference call. If you would like to register, please contact Walbrook PR on 020 7933 8780

or email    [e-mail] 
 
     EKF Diagnostics Holdings plc                                        www.ekfdiagnostics.com 
     Christopher Mills, Non-executive Chairman                        Tel: [phone] 
     Julian Baines, CEO 
     Richard Evans, FD & COO 
 
     N+1 Singer                                                              Tel: [phone] 
     Aubrey Powell / George Tzimas (Corporate 
      Finance) 
      Tom Salvesen (Corporate Broking) 
 
     Walbrook PR Limited                        Tel: [phone] or [e-mail] 
     Paul McManus / Lianne Cawthorne                   Mob: [phone] 
                                                                                        391 303 
 
 

About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )

EKF Diagnostics Holdings plc specialises in the development, production and worldwide distribution of point-of-care analyzers and clinical chemistry reagents for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF is also a bulk manufacturer of enzymes and has custom manufacturing facilities in the USA for a variety of life science products.

In 2020, EKF developed a range of COVID-19 testing products including PrimeStore MTM, an FDA-approved and CE marked sample containment device that allows the safe handling, transportation and analysis of test swabs and samples, which it manufactures under licence, and COVID-SeroKlir, a leading ELISA-based antibody test from Kantaro Biosciences that provides a precise measurement of COVID-19 IgG antibodies.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORMZGGFNZVGMZM

(END) Dow Jones Newswires

March 03, 2021 02:00 ET (07:00 GMT)